Hepatitis C - MM+M - Medical Marketing and Media

Hepatitis C

All articles by Hepatitis C

Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Virginia Lau
August 31, 2017
11:00 am

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Five things for pharma marketers to know: Friday, August 4, 2017
Five things for pharma marketers to know: Friday, August 4, 2017
Jaimy Lee
August 4, 2017
2:45 pm

AbbVie’s new HCV drug is cheaper than Gilead’s Harvoni; Lilly’s experimental migraine drugs beats placebo; Fitbit to launch smartwatch

Gilead’s educational campaign boosted HCV diagnosis rates for baby boomers
Gilead’s educational campaign boosted HCV diagnosis rates for baby boomers
Jaimy Lee
July 27, 2017
2:20 pm

An unbranded campaign encouraging baby boomers to get tested for hepatitis C helped boost screening and diagnosis numbers, which in turn upped sales of its HCV therapies.

Five things for pharma marketers to know: Monday, July 24, 2017
Five things for pharma marketers to know: Monday, July 24, 2017
Virginia Lau
July 24, 2017
2:55 pm

Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment

Five things for pharma marketers to know: Monday, April 10, 2017
Five things for pharma marketers to know: Monday, April 10, 2017
Virginia Lau
April 10, 2017
2:50 pm

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Five things for pharma marketers to know: Wednesday, March 29, 2017
Five things for pharma marketers to know: Wednesday, March 29, 2017
Jaimy Lee
March 29, 2017
2:25 pm

A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year

Five things for pharma marketers to know: Tuesday, March 14, 2017
Five things for pharma marketers to know: Tuesday, March 14, 2017
Virginia Lau
March 14, 2017
2:45 pm

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Thursday, December 29, 2016
Five things for pharma marketers to know: Thursday, December 29, 2016
Jaimy Lee
December 29, 2016
2:55 pm

Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products

Gilead’s Meyers on making deals and finding unmet patient needs
Gilead’s Meyers on making deals and finding unmet patient needs
Virginia Lau
November 29, 2016
3:19 pm

The drugmaker’s new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Five things for pharma marketers to know: Wednesday, October 5, 2016
Five things for pharma marketers to know: Wednesday, October 5, 2016
Jaimy Lee
October 5, 2016
1:15 pm

The FDA to require black-box warnings for hep.-C drugs; AstraZeneca’s Brilinta fails to meet study goals; ICER says PD-1s are too pricey

  • Culture drives the company

    Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

  • From Our Partners